Loading…
← CockpitCompetitor Analysis › 002082.SZ Wanbangde Pharmaceutical Holding Group Co., Ltd. Class AOpen in the cockpit ↗

Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A002082.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.

Momentum laggard 14
Mkt cap
$823M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-6.6 pp
WACC 6.9%
Hurdle
+67 pp
Req g minus delivered
Close · CNYCN¥9.06
1D-1.5%
1W-12.9%
1M-20.5%
3M-17.3%
6M-52.1%
YTD-35.0%
1Y-39.6%
ATR %6.9%
52w lowhigh75.0% off high

What Wanbangde Pharmaceutical does

Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.

Products and services

  • Pharmaceutical manufacturing subsidiaries

Where it sits in the supply chain

  • Pharmaceuticals
  • Holding company

Moat: none. Diversified holding structure with no single dominant franchise.

Headquarters: Zhejiang, China · Employees: 1,348

Wanbangde Pharmaceutical at a glance

Size Wanbangde Pharmaceutical (002082.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $823M, the 2531st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.06 on 18 Nov 2026.

Performance Over six months the shares fell 52.1%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue fell 38.4% over the last twelve months (peer median +7.7%); the operating margin is -10.2% (peer median 10.0%).

Valuation It trades at 7.0× enterprise value to sales against a peer median of 2.9× (4th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is -39%, so the hurdle is +67 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.6 points below its cost of capital (6.9% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 91002082.SZ 50
Six months, rebased to 100: Wanbangde Pharmaceutical against the median of its 20 peers (local-currency closes).

Wanbangde Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥854MCN¥1.11BCN¥1.44BCN¥1.53BCN¥1.77B
Revenue growth—-22%-6%-13%—
Gross profitCN¥445MCN¥317MCN¥543MCN¥568MCN¥862M
EBITDAn/a-CN¥23.1MCN¥184MCN¥169MCN¥341M
Net income-CN¥146M-CN¥167MCN¥55.4MCN¥49.2MCN¥93.3M
Free cash flowCN¥707MCN¥303MCN¥32.3M-CN¥199M-CN¥406M
Capital expenditure-CN¥13.5MCN¥302MCN¥88.4MCN¥129MCN¥167M
Total debtCN¥1.03BCN¥1.17BCN¥1.06BCN¥1.01BCN¥912M

Quarterly statements and history in the cockpit →

Wanbangde Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-50%-25%0%+25%6032290008133002676078COLLSUVEN688073RIGL688621SANOFIORIC688176086450GUDIRWD069620CRVS002082.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Wanbangde Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×250×500×750×6032290008133002676078SUVEN688176086450GUD002082.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wanbangde Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-40%-20%0%20%6078COLL688073RIGLSANOFI086450002082.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Wanbangde Pharmaceutical is the large dot.

Wanbangde Pharmaceutical competitors and peer comparison

How Wanbangde Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wanbangde Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002082.SZPeer medianRank in peer set
1-month return-20.5%-7.0%2nd lowest of 20
6-month return-52.1%-7.9%lowest of 19
Distance from 52-week high-75.0%-34.1%lowest of 20
Revenue growth (TTM)-38.4%+7.7%lowest of 18
Operating margin-10.2%10.0%6th lowest of 18
EV / Sales7.0×2.9×4th most expensive of 17
Growth the price implies (Req g, 7 yrs)27.7%4.6%most demanding of 8
Growth delivered (Del g)-39.5%+20.3%lowest of 8
Hurdle (Req g minus delivered)+67.2 pp-14.8 ppmost demanding of 8
ROIC minus cost of capital-6.6 pp-0.7 pp5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a

Questions

Which companies are Wanbangde Pharmaceutical's closest peers?
The cockpit's peer set: Zhejiang Ausun Pharmaceutical (603229.SS), Dezhan Healthcare (000813.SZ), Hunan Er-Kang Pharmaceutical (300267.SZ), Hygeia Healthcare (6078.HK), Collegium Pharmaceutical (COLL), Suven Life Sciences (SUVEN.NS), Bide Pharmatech (688073.SS), Rigel Pharmaceuticals (RIGL).
Is Wanbangde Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 7.0× against a peer median of 2.9×, 4th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is -39%, so the hurdle is +67 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Wanbangde Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -52.1% against -7.9% for the median peer; over one year -39.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.